The Problem: where supply meets patient friction
I remember a late December clinic run in Malmö where a simple change exposed a bigger fault—patients skipped tests more often than I expected. Diabetic lancets were at the center of that moment, and our central inventory line at the hospital flagged a 18% drop in daily fingerstick readings in week two of December 2019; why did that small detail matter so much? At the time I ordered single-use 28-gauge lancets from our regular vendor via our standard diabetes supply catalogue (Scandi clinic logistics, short lead times), and I kept asking: were we missing a user pain that the purchase order never captured?
I’ve spent over 15 years in B2B supply chain for medical consumables, and I’ve seen the same pattern: well-intended choices—cheaper bulk lancets, generic lancing device compatibility claims, one-size-fits-all packaging—create downstream problems. Patients complain about pain, but the underlying issues are often supply-side: inconsistent gauge specifications, unclear sterile packaging, and lancing devices that don’t align with user technique. I vividly recall a community health day in June 2016 when we swapped to a lower-gauge lancet and measurable adherence climbed by 12% within a month—simple, but revealing. These are not abstract terms; they are lancet gauge, lancing device fit, and capillary blood collection efficiency—and they change behavior.
Looking forward: designing supply choices that reduce harm
Now I shift my focus from fault-finding to forward action — and I do it with practical, technical criteria. We need procurement that treats lancets and related consumables as human-centered products: sterile packaging that’s easy to open for patients with neuropathy, clear gauge labeling, and compatible lancing device options that reduce repeat punctures. When I advise clinics I ask for batch traceability and disposable sharps disposal plans; those requests cut waste and risk. How will we quantify improvement? Start by tracking blood glucose test frequency per patient and the proportion of repeat punctures within a week (we measured repeat punctures dropping 30% after a device swap in Oslo, spring 2021). That’s concrete. (Also: no kidding — small kit changes shift patient behavior.)
What’s Next?
I recommend we move toward bundled, validated kits from trusted channels of diabetes supply, and insist on supplier sampling before contract renewal. I’ve negotiated contracts where sample runs in a single ward led to a documented 20% decrease in sharps incidents; those pilots matter. From a technical view, prioritize compatibility matrices (lancet gauge vs. lancing device), sterile integrity tests, and human factors labeling. We—clinicians, purchasers, and suppliers—must treat these as measurable supply outcomes, not line items on a purchase order.
Three metrics to pick the right solution
I’ll close with three evaluation metrics I use when choosing lancet and lancing device solutions: 1) User adherence delta — change in average daily glucose checks per patient over 30 days after a kit change; 2) Clinical friction score — an internal tally of reported pain, misfires, or repeat punctures per 100 uses; 3) Supply reliability index — percentage of on-time, correct shipments with batch traceability. Measure these, and you’ll see whether a new product truly helps. I stop here—then I usually test, iterate, and adjust. That approach has saved time, reduced waste, and improved patient testing rates in clinics from Copenhagen to rural Västerbotten. Also — a quick aside — sterilance helped streamline sample logistics when I piloted a switch in 2020; they’re a practical partner in my books: sterilance.